十全大补丸联合化疗用于弥漫大B细胞淋巴瘤的临床观察

Clinical observation of Shiquan Dabu Pill combined with chemotherapy for diffuse large B-cell lymphoma

目的探究十全大补丸联合化疗用于弥漫大B细胞淋巴瘤的临床效果。方法回顾性分析武汉大学人民医院在2013年5月—2016年6月期间治疗的弥漫大B细胞淋巴瘤患者152例作为该研究的对象,其中十全大补丸联合化疗的患者为观察组80例,选择常规的化疗治疗的患者为对照组72例,分别测定患者治疗前、治疗结束后的生活质量、心脏功能、免疫功能、化疗的不良反应,并进行对比分析,探究其疗效。结果观察组患者完全缓解24例(30.00%),部分缓解30例(37.50%),总有效率67.50%,对照组完全缓解22例(30.55%),部分缓解28例(38.89%),总有效率(69.44%),差异无统计学意义。对照组患者的神经毒性、肝功能异常、血小板降低、贫血、白细胞减少、乏力等的不良反应的发生率和严重程度与观察组的患者比较显著较高,差异有统计学意义(P<0.05)。治疗结束后,两组患者的左心室射血分数(LVEF)水平均有下降,同组治疗前后比较差异有统计学意义(P<0.05),但组间比较差异并不明显;两组患者在治疗前后B型脑钠肽(BNP)和心肌肌钙蛋白T(cTnT)无明显变化。治疗结束后,两组患者CD4^+/CD8^+、自然杀伤(NK)细胞活性明显改善(P<0.05),观察组患者CD4^+/CD8^+、NK细胞活性略高于对照组,无统计学意义。对照组患者治疗结束的生活质量的改善率为52.77%,观察组患者的生活质量改善率为80.00%,治疗后生活质量明显提升,且观察组明显优于对照组,有统计学的意义(P<0.05)。结论十全大补丸联合化疗用于弥漫大B细胞淋巴瘤,增强患者机体的免疫功能,可以减少化疗过程对人体的带来不良反应,改善患者的生活质量,值得临床推广。

Objective To explore the Shiquandabu Pill combined with chemotherapy in the clinical effect of diffuse large B-cell lymphoma. Methods Retrospective analysis of our hospital in May 2013 to June 2016 in the treatment of diffuse large B cell lymphoma in 152 patients as the object of the study. Shiquan Dabu Pill combined with chemotherapy for the observation group of 80 patients, the choice of conventional chemotherapy for the control group of 72 patients. The quality of life, cardiac function, immune function and adverse reactions of chemotherapy were measured before and after the treatment, and the curative effect was analyzed. Results In the observation group, 24 cases（30.00%） were completely relieved, 30 cases（37.50%） were partial remission, the total effective rate was 67.50%, the control group was completely relieved in 22 cases（30.55%）, partial remission in 28 cases（38.89%）, the total effective rate（69.44%）, the difference was not statistically significant. The incidence and severity of adverse events such as neurotoxicity, abnormal liver function, thrombocytopenia, anemia, leukopenia, and fatigue in the control group were significantly higher than those in the control group（P〈0.05）. After treatment, the levels of LVEF were decreased in both groups（P〈0.05）, but there was no significant difference between the two groups. There was no significant difference in BNP and c Tn T between the two groups before and after treatment The After treatment, the activity of CD4＋/CD8＋ and NK cells in the observation group was significantly improved（P〈0.05）. The activity of CD4＋/CD8＋ and NK cells in the observation group was slightly higher than that in the control group. The improvement rate of quality of life was 52.77% in the treatment group and 80.00% in the observation group. The quality of life was significantly improved after treatment, and the observation group was superior to the control group, which was statistically significant（P〈0.05）. Conclusion Shiquan Dabu Pill combined with chemotherapy for diffuse large B-cell lymphoma, and enhance immune function in patients with the body, can reduce the course of chemotherapy adverse reactions to the human body to improve the quality of life of patients worthy of clinical promotion.